Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
17 Aug 25
Updated
17 Aug 25
AnalystConsensusTarget's Fair Value
US$9.62
81.4% undervalued intrinsic discount17 Aug
US$1.79
1Y
-55.1%7D
-16.9%